Clinical Trials Browser

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Phase 1 Withdrawn

Sarcoma

Hemangiosarcoma

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

139 enrolled

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Phase 2 Active not recruiting

13 enrolled 9 charts

Sarcoma

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Clinical Trials

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

I-SPY

ANGIO-TAX+

PANTHR-S

CAIR

REGOSTA

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)